CYCLERION

Welcome to the Brand page for “CYCLERION”, which is offered here for Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, preparations that stimulate guanylate cyclases (sgc), increase the concentration of nitric oxide (no), increase the concentration of cyclic guanosine monophosphate (cgmp), upregulate the no-sgc-cgmp (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the no-sgc-cgmp (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; pharmaceutical preparations, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds;.

Its status is currently believed to be active. Its class is unavailable. “CYCLERION” is believed to be currently owned by “Cyclerion Therapeutics, Inc.”